Mobilion Ventures

Mobilion Ventures spent its first chapter as a mobility-focused fund and is now visibly extending into the bio-convergence territory where smart sensors, edge AI, and miniaturized hardware collide with healthcare. The Tel Aviv firm’s heritage in vehicle-grade systems and IoT translates more directly into clinical-grade hardware and continuous monitoring than the pitch sounds at first.

The thesis follows the technology rather than the vertical. Mobility taught the team how to evaluate sensor stacks, real-time inference, low-power compute, and reliability in environments where failure is expensive. Those skills map cleanly onto AI/ML in healthcare, which is where the fund is increasingly deploying capital. Expected territory includes wearables and patient monitoring, computer vision in clinical workflows, hardware-integrated diagnostics, and the AI layer that sits on top of any of these systems. The fund is selective rather than thesis-broad, and it tends to back companies where the defensibility is technical rather than purely commercial.

Checks land in the one to five million dollar band, with activity at Seed and Series A. Mobilion will lead Seed rounds where the technology fit is clear, and is comfortable participating at Series A in companies it has tracked or where the syndicate composition makes a partnership constructive. Geography centers on Israeli founders, with US and European market focus expected from early on. The fund’s connections in mobility-adjacent industrials and large enterprise customers give it a useful adjacency for healthcare startups whose buyers include hospital systems, fleet operators, and large employers running occupational health programs.

The team carries the technical discipline of a hardware fund rather than the pattern-matching habits of generalist software investors. Founders should expect serious engagement with sensor design, model deployment, and the systems engineering that determines whether a hardware-software product actually scales. The diligence process is not a polite walk through the deck. It is a working session, and the better founders find it useful rather than annoying.

In practice, the value-add concentrates where Mobilion’s heritage gives it leverage. The fund is helpful on supply chain and manufacturing, on integrating AI models into resource-constrained edge environments, and on selling into large industrial buyers whose procurement processes are closer to healthcare’s than most software founders realize. Mobilion is direct that pure SaaS plays without a hardware or sensing dimension are not its sweet spot. For founders building AI-driven healthcare hardware, continuous monitoring devices, or clinical computer vision systems, the fund’s adjacency to mobility is a feature rather than a quirk. The conversation will be technically grounded, the diligence will be specific, and the post-investment work will land in the parts of the business that purely commercial investors usually skip. Founders who want a partner that takes hardware seriously, and who can connect them to industrial enterprise relationships outside the usual healthcare circle, will find Mobilion a more substantive option than the description on its homepage suggests.